Loading
Copies of the big antibody drugs are approved and cheaper, but uptake depends on each prescriber; letting the pharmacy substitute the biosimilar unless the oncologist objects would move most patients within a year.
FDA-approved biosimilars of trastuzumab, bevacizumab, rituximab and pegfilgrastim have been on the US market since 2019. IQVIA estimated that biosimilars saved $56 billion over the decade to 2022 and projected $181 billion more over 2023 to 2027. Uptake still varies widely by practice because substitution requires a prescriber decision, a payer preference and a purchasing contract to line up. A default-substitution rule (opt-out rather than opt-in), combined with the flat-fee payment idea, removes the friction. NHS England and several European systems achieved over 90% uptake this way.
Shares Trastuzumab biosimilars, Biosimilar, Prices and value, Rituximab.
Shares Biosimilar, Prices and value, Rituximab, Bevacizumab.
Shares Trastuzumab biosimilars, Biosimilar, Prices and value, Trastuzumab.
Shares Trastuzumab biosimilars, Biosimilar, Prices and value, Trastuzumab.
Shares Trastuzumab biosimilars, Trastuzumab.
Shares Biosimilar, Rituximab.
Shares Trastuzumab biosimilars, Trastuzumab.
Shares Biosimilar, Prices and value.